SCHEMBL22290754

SCHEMBL22290754

CC1(C)OB(c2cccc(COC3CCC(O)CC3)c2)OC1(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 4/20 0.48
LPL P06858 3/20 0.48
CARM1 Q86X55 5/20 0.37
PRMT6 Q96LA8 5/20 0.37
OPRM1 P35372 2/20 0.34
OPRL1 P41146 2/20 0.34
PRMT8 Q9NR22 2/20 0.34
TDP2 O95551 1/20 0.34
DGAT1 O75907 1/20 0.34
PRMT3 O60678 1/20 0.34
F11 P03951 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
HTR7 P34969 1/20 0.33
HTR2B P41595 1/20 0.33
HTR3A P46098 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HTR4 Q13639 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290349 0.86 LIPG (0.49) LIPGLPLCARM1PRMT6OPRM1
SCHEMBL22290622 0.84 LPL (0.47) LIPGLPLCARM1PRMT6PRMT8
SCHEMBL22290682 0.82 LIPG (0.47) LIPGLPLCARM1PRMT6OPRM1
SCHEMBL31068330 0.82 LIPG (0.47) LIPGLPLCARM1PRMT6OPRM1
SCHEMBL22291043 0.81 LIPG (0.49) LIPGLPLCARM1PRMT6PRMT8
SCHEMBL18579622 0.78 LIPG (0.48) LIPGLPLCARM1PRMT6OPRM1
SCHEMBL18579621 0.78 LIPG (0.48) LIPGLPLCARM1PRMT6OPRM1
SCHEMBL27202172 0.77 LPL (0.53) LIPGLPLOPRM1OPRL1DGAT1
SCHEMBL19464259 0.76 LIPG (0.61) LIPGLPLTDP2DGAT1F11
SCHEMBL20768134 0.76 LIPG (0.51) LIPGLPLTDP2DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB LIPG 2836/4885LPL 1810/4885CARM1 465/4885
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB LIPG 2836/4885LPL 1810/4885CARM1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.